Benign prostatic hyperplasia: Counting the cost of its management

BJU International

Volumn 105, Issue 7, 2010, Pages 901-902

  Kirby, Roger S ^a   Kirby, Mike ^a   Fitzpatrick, John M ^b  

^a Prostate Centre   (United Kingdom)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ACUTE URINARY RETENTION; COST BENEFIT ANALYSIS; DRUG COST; HUMAN; NOTE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; URINE RETENTION;

HEALTH CARE COSTS; HUMANS; MALE; PROSTATIC HYPERPLASIA; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 77749286437     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09274.x     Document Type: Note

References (11)

1. Thomas K, Oades G, Taylor-Hay C, Kirby RS. Acute urinary retention: what is the impact on patient's quality of life? BJU Int 2005 95 : 72 6
2. HES Database. 2007/2008: AUR report. Available at: http://www.hesonline. nhs.uk/. Accessed 12 February 2010
3. Roehrborn CG, Marks LS, Fenter T et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004 63 : 709 715
4. Barkin M, Guimara G, Jacobi G et al. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5a-reductase inhibitor dutasteride. Eur Urol 2003 44 : 461 466
5. Roehrborn C, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008 179 : 616 621
6. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 2398
7. Drummond MF, McGuire AJ, Black NA, Petticrew M, McPherson CK. Economic burden of treated benign prostatic hyperplasia in the United Kingdom. Br J Urol 1993 71 : 290 296
8. Kirby RS, Kirby MG, Fitzpatrick JM. Facilitating the medical management of benign prostatic hyperplasia in primary care. BJU Int 2009 104 : 751 753
9. Speakman M, Kirby RS, Joyce A et al. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004 93 : 985 990
10. Tanguay S, Awde M, Brook G et al. Diagnosis and management of benign prostatic hyperplasia in primary care. Can Urol Assoc J 2009 3 (Suppl S92 100
11. Kirby RS, Fitzpatrick JM, Kirby MG, Fitzpatrick A. Shared Care for Prostatic Diseases. Oxford : Isis Medical Media, 1995 RS, Chisholm G, Chapple C et al. Shared care between general practitioners and urologists in the management of benign prostatic hyperplasia: a survey of attitudes among clinicians. J R Soc Med 1995 88 : 284P 288P